Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions
Evotec AG announced a new integrated drug discovery alliance with LEO Pharma. The collaboration goal is to generate new leads against innovative targets for a range of dermatological conditions and initially runs for two years.
The collaboration leverages Evotec’s industry-leading hit identification platform including the extensive screening, structural biology and fragment-based drug design capabilities and expertise together with LEO Pharma’s 110-year track record of drug development and advancing science in dermatology. Evotec’s integrated discovery scientists will work in a joint team with scientists from LEO Pharma. The alliance will receive further support with high-value drug development and discovery ADME-Tox services.
Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “We are delighted to partner with LEO Pharma on this exciting project, which leverages our industry-leading hit generation platform. Working together, we are convinced we will find innovative therapeutic approaches to dermatological conditions with a high unmet medical need.”
Dr Thorsten Thormann, Vice President, Research at LEO Pharma, said: “Innovation through partnerships plays a key role in LEO Pharma’s approach to developing new medicines. We are confident that our alliance with Evotec will further strengthen our research and help us expedite the discovery of novel small molecule therapeutics for skin diseases, for which there are large unmet medical needs, thus helping even more patients in the future.”
No financial details of this fee-for-service collaboration were disclosed.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Variants in BRCA1/2 and MMR genes in children with cancer - Genetic testing not recommended in healthy children
A*STAR Joins Forces with Cytos to Combat Hand, Foot and Mouth Disease
New substance overcomes treatment-resistance in leukaemia
Simulations show how to make gene therapy more effective
Researchers discover an alternative to PEG - rPEG as a new type of Poly(ethylene glycol): random chains offer multiple advantages for medical application
Billion-euro takeover: Roche joins the fight against obesity
Blood tests could predict survival odds for patients with metastatic cancer - By measuring the proportion of DNA in the bloodstream that comes from a tumor, liquid biopsies may be able to guide treatment discussions
Sealing leaks in the stomach or intestine - Start-up planned
A new generation of particle accelerators aims at taking cancer therapy, drug detection and material analysis to a higher level - Additively manufactured copper components for linear accelerators
Molecular Zippers Hold Golgi Membranes Together
TcLand Expression appoints its Scientific and Medical Advisory Board dedicated to Rheumatology
